ArticleBreast cancer research : BCR2017

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.

Tesa M Severson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.